INTRODUCTION AND HYPOTHESIS: Mesh-augmented reconstructive surgery for pelvic organ prolapse (POP) does not meet clinical expectations. A tissue-engineered fascia equivalent needs to be developed. METHODS: Human vaginal fibroblasts (HVFs) from 10 patients were characterized in vitro. Eligible HVFs and a biodegradable scaffold were used to fabricate a fascia equivalent, which was then transplanted in vivo. RESULTS: The cultured HVFs were divided into high (n = 6) or low (n = 4) collagen I/III ratio groups. Cells of the high-ratio group exhibited significantly higher proliferation potential than those of the low-ratio group (P < 0.05). A fascia equivalent was made with HVFs of the high-ratio group. In the subsequent animal study, a well-organized neo-fascia formation containing HVFs could be traced up to 12 weeks after transplantation. CONCLUSIONS: Our results suggest that a tissue-engineered fascia could be developed from HVFs in vitro and in vivo, which might be an effective treatment for POP in the future.
INTRODUCTION AND HYPOTHESIS: Mesh-augmented reconstructive surgery for pelvic organ prolapse (POP) does not meet clinical expectations. A tissue-engineered fascia equivalent needs to be developed. METHODS:Human vaginal fibroblasts (HVFs) from 10 patients were characterized in vitro. Eligible HVFs and a biodegradable scaffold were used to fabricate a fascia equivalent, which was then transplanted in vivo. RESULTS: The cultured HVFs were divided into high (n = 6) or low (n = 4) collagen I/III ratio groups. Cells of the high-ratio group exhibited significantly higher proliferation potential than those of the low-ratio group (P < 0.05). A fascia equivalent was made with HVFs of the high-ratio group. In the subsequent animal study, a well-organized neo-fascia formation containing HVFs could be traced up to 12 weeks after transplantation. CONCLUSIONS: Our results suggest that a tissue-engineered fascia could be developed from HVFs in vitro and in vivo, which might be an effective treatment for POP in the future.
Authors: L K Carr; D Steele; S Steele; D Wagner; R Pruchnic; R Jankowski; J Erickson; J Huard; M B Chancellor Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2008-06
Authors: Wenjun Zong; Halina M Zyczynski; Leslie A Meyn; Susan C Gordy; Pamela A Moalli Journal: Am J Obstet Gynecol Date: 2007-04 Impact factor: 8.661
Authors: Michael Mitterberger; Rainer Marksteiner; Eva Margreiter; Germar M Pinggera; Daniela Colleselli; Ferdinand Frauscher; Hanno Ulmer; Martin Fussenegger; Georg Bartsch; Hannes Strasser Journal: BJU Int Date: 2007-08-30 Impact factor: 5.588
Authors: Taeyoung Kim; Indumathi Sridharan; Bofan Zhu; Joseph Orgel; Rong Wang Journal: Mater Sci Eng C Mater Biol Appl Date: 2015-01-07 Impact factor: 7.328
Authors: Daniela Ulrich; Sharon Lee Edwards; Kai Su; Ker Sin Tan; Jacinta F White; John A M Ramshaw; Camden Lo; Anna Rosamilia; Jerome A Werkmeister; Caroline E Gargett Journal: Tissue Eng Part A Date: 2013-11-21 Impact factor: 3.845
Authors: Sabiniano Roman Regueros; Maarten Albersen; Stefano Manodoro; Silvia Zia; Nadir I Osman; Anthony J Bullock; Christopher R Chapple; Jan Deprest; Sheila MacNeil Journal: Biomed Res Int Date: 2014-07-17 Impact factor: 3.411
Authors: Christopher J Hillary; Sabiniano Roman; Anthony J Bullock; Nicola H Green; Christopher R Chapple; Sheila MacNeil Journal: PLoS One Date: 2016-03-16 Impact factor: 3.240